tradingkey.logo

Resmed Inc

RMD
265.260USD
-1.220-0.46%
Close 10/23, 16:00ETQuotes delayed by 15 min
38.83BMarket Cap
27.72P/E TTM

Resmed Inc

265.260
-1.220-0.46%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Resmed Inc

Currency: USD Updated: 2025-10-23

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Resmed Inc's Score

Industry at a Glance

Industry Ranking
34 / 204
Overall Ranking
104 / 4685
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
292.754
Target Price
+9.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Resmed Inc Highlights

StrengthsRisks
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.86% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.15B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 22.19%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 22.19%.
Undervalued
The company’s latest PE is 27.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.83M shares, decreasing 4.98% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.68M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-23

The company's current financial score is 9.68, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.35B, representing a year-over-year increase of 10.20%, while its net profit experienced a year-over-year increase of 29.93%.

Score

Industry at a Glance

Previous score
9.68
Change
0

Financials

9.47

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

8.99

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

9.93

Resmed Inc's Company Valuation

Currency: USD Updated: 2025-10-23

The company’s current valuation score is 7.65, which is higher than the Healthcare Equipment & Supplies industry's average of 7.16. Its current P/E ratio is 27.78, which is 56.64% below the recent high of 43.52 and 21.46% above the recent low of 21.82.

Score

Industry at a Glance

Previous score
7.65
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 34/204
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-23

The company’s current earnings forecast score is 7.44, which is lower than the Healthcare Equipment & Supplies industry's average of 7.72. The average price target for Resmed Inc is 299.00, with a high of 325.00 and a low of 215.00.

Score

Industry at a Glance

Previous score
7.44
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts
Buy
Current Rating
292.754
Target Price
+9.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

95
Total
4
Median
7
Average
Company name
Ratings
Analysts
Resmed Inc
RMD
20
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-23

The company’s current price momentum score is 6.57, which is lower than the Healthcare Equipment & Supplies industry's average of 7.16. Sideways: Currently, the stock price is trading between the resistance level at 279.05 and the support level at 257.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.67
Change
-0.1

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.895
Sell
RSI(14)
38.562
Neutral
STOCH(KDJ)(9,3,3)
20.080
Neutral
ATR(14)
5.291
High Vlolatility
CCI(14)
-101.996
Sell
Williams %R
90.078
Oversold
TRIX(12,20)
-0.088
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
267.892
Sell
MA10
269.424
Sell
MA20
273.013
Sell
MA50
275.888
Sell
MA100
269.263
Sell
MA200
251.141
Buy

Institutional Confidence

Currency: USD Updated: 2025-10-23

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.37. The latest institutional shareholding proportion is 64.98%, representing a quarter-over-quarter decrease of 1.29%. The largest institutional shareholder is The Vanguard, holding a total of 18.68M shares, representing 12.80% of shares outstanding, with 3.77% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
18.68M
+1.36%
BlackRock Institutional Trust Company, N.A.
8.67M
-2.41%
State Street Investment Management (US)
6.62M
+0.98%
Geode Capital Management, L.L.C.
4.22M
+2.40%
Walter Scott & Partners Ltd.
3.29M
-2.18%
Morgan Stanley & Co. LLC
1.40M
-50.77%
Norges Bank Investment Management (NBIM)
1.19M
+129.03%
Northern Trust Investments, Inc.
1.17M
-0.08%
Invesco Capital Management LLC
Star Investors
1.16M
-2.52%
BlackRock Asset Management Ireland Limited
1.13M
+4.31%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-23

The company’s current risk assessment score is 9.30, which is higher than the Healthcare Equipment & Supplies industry's average of 4.64. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
9.30
Change
0
Beta vs S&P 500 index
0.88
VaR
+2.98%
240-Day Maximum Drawdown
+20.61%
240-Day Volatility
+29.50%

Return

Best Daily Return
60 days
+4.38%
120 days
+4.38%
5 years
+18.89%
Worst Daily Return
60 days
-3.12%
120 days
-3.12%
5 years
-18.50%
Sharpe Ratio
60 days
-0.75
120 days
+1.40
5 years
+0.32

Risk Assessment

Maximum Drawdown
240 days
+20.61%
3 years
+44.12%
5 years
+54.72%
Return-to-Drawdown Ratio
240 days
+0.39
3 years
+0.15
5 years
+0.08
Skewness
240 days
+0.13
3 years
-0.04
5 years
-0.23

Volatility

Realised Volatility
240 days
+29.50%
5 years
+30.87%
Standardised True Range
240 days
+2.18%
5 years
+2.07%
Downside Risk-Adjusted Return
120 days
+213.24%
240 days
+213.24%
Maximum Daily Upside Volatility
60 days
+16.96%
Maximum Daily Downside Volatility
60 days
+18.29%

Liquidity

Average Turnover Rate
60 days
+0.64%
120 days
+0.68%
5 years
--
Turnover Deviation
20 days
-2.22%
60 days
-9.28%
120 days
-3.51%

Peer Comparison

Healthcare Equipment & Supplies
Resmed Inc
Resmed Inc
RMD
7.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Repligen Corp
Repligen Corp
RGEN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioLife Solutions Inc
BioLife Solutions Inc
BLFS
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI